Patent Circle has compiled a list of more than 100 active pharmaceutical ingredients (APIs) going off-patent in the US from the year 2009 – 2015. At least 24 APIs will go off-patent in the year 2009 including Levetiracetam (more than USD 700 million US sales in 2007), Lamotrigine (USD 2.2 billion US sales for twelve months that ended March 2008), Sumatriptan (nearly USD 1 billion US sales in 2007), Valacyclovir (USD 1.3 billion US sales in 2007), Topiramate (USD 2.2 billion US sales for twelve months that ended March 2008) and Tamsulosin (USD 1.3 billion US sales for twelve months that ended September 2007). Moreover, two of the biggest blockbuster drugs Atorvastatin Calcium (USD 6 billion US sales in 2007) and Clopidogrel Bisulphate (USD 3 billion US sales in 2007) will finally reaching end of their patent protection in 2010 and 2011.
Undoubtedly, there is a big opportunity coming up for generic players with many drug compounds going off-patent in next 6 years and our list will keep generic players stay tuned with drug expiries. Readers may buy our report by writing to us at email@example.com. We are confident that our report will help to seize business opportunity in growing competitive generic space.